Hemogenyx Pharmaceuticals Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HOPHF research report →
Companywww.hemogenyx.com
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
- CEO
- Vladislav Sandler
- IPO
- 2021
- Employees
- 16
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $15.84M
- P/E
- -4.14
- P/S
- 0.00
- P/B
- 33.81
- EV/EBITDA
- -7.20
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -2807.75%
- ROIC
- -148.02%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-9,760,364 · -73.70%
- EPS
- $-2.20 · -3.29%
- Op Income
- $-6,980,258
- FCF YoY
- 16.89%
Performance & Tape
- 52W High
- $2.33
- 52W Low
- $0.04
- 50D MA
- $2.33
- 200D MA
- $2.33
- Beta
- 2.31
- Avg Volume
- 13.61K
Get TickerSpark's AI analysis on HOPHF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HOPHF Coverage
We haven't published any research on HOPHF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HOPHF Report →